Pharmaceutical News

RSS

Elafin protein protects against inflammatory diseases

This protection is provided by a human protein, Elafin, which is artificially introduced into dairy produce bacteria (Lactococcus lactis and Lactobacillus casei). In time, this discovery could be useful for individuals suffering from chronic inflammatory diseases such as Crohn's disease or ulcerative colitis.

7 Nov 2012

Scientists show how sorafenib can be dangerous to the heart

Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.

7 Nov 2012

IRIN examines intellectual property protection in South Africa

IRIN examines how patents and intellectual property protection in South Africa affects patients' access to medicines. "A form of intellectual property protection, patents are typically awarded to companies that can prove their product is new," IRIN writes, adding, "Not so in South Africa, say activists and researchers, who claim the country's patent system allows pharmaceutical companies to apply for new patents on existing drugs based on immaterial changes -- like adding table salt to a formulation or changing a pill's color."

7 Nov 2012

Drug trio may reduce eliminate cardiac side effects of doxorubicin

Combining cancer medication with a drug for erectile dysfunction and one for heart transplants helped kill cancer cells and protected the heart from damage, in a study presented at the American Heart Association's Scientific Sessions 2012.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Cause of heart attacks or strokes may be different in some patients treated with anti-platelet drugs

The cause of heart attacks or strokes among some patients treated with anti-platelet drugs may be different than for patients who have undergone surgical procedures to restore blood flow, according to researchers at Duke Medicine.

7 Nov 2012

LipoScience presents key findings related to LDL-P and CVD at AHA annual meeting

LipoScience, Inc., an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases, today presented key findings related to lipoprotein particles (LDL-P) and cardiovascular disease at the Annual Meeting of the American Heart Association (AHA) in Los Angeles.

7 Nov 2012

FDA grants Priority Review to ImmunoGen’s trastuzumab emtansine BLA

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech, a member of the Roche Group, has disclosed that the U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for trastuzumab emtansine and granted it Priority Review.

7 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

NAI receives U.S. patent allowance for sustained release beta-alanine products

Natural Alternatives International, Inc., a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance of its patent application directed to sustained release formulations of beta-alanine.

6 Nov 2012

Geldanamycin degrades VEGFR2 protein that triggers blood vessel growth

The drug, geldanamycin, is well known for attacking a protein associated with the spread of breast cancer. However, a laboratory-based study found it also degraded a different protein that triggers blood vessel growth.

6 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

Seniors can play an important role in reducing risks associated with prescription medications

Common medication to treat insomnia, anxiety, itching or allergies can have a negative impact on memory or concentration in the elderly, according to Dr. Cara Tannenbaum, Research Chair at the Institut universitaire de g-riatrie de Montr-al (IUGM, Montreal Geriatric University Institute) and Associate Professor of Medicine and Pharmacy at the University of Montreal (UdeM).

6 Nov 2012

Sorin Group’s Mitroflow Valsalva Conduit now available in the U.S.

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the U.S. commercial launch of the Mitroflow Valsalva Conduit, the only Valsalva conduit graft approved by the U.S. Food and Drug Administration (FDA) for use in combination with an aortic tissue valve.

6 Nov 2012

Low-dose aspirin effective at preventing serious blood clots

Low-dose aspirin is a cheap and effective way to prevent potentially deadly blood clots in the leg or the lungs in patients who have had a previous blood clot a new study shows.

6 Nov 2012

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.

6 Nov 2012

Study shows how local anesthetics can improve motor skills of patients after stroke

Painkilling drugs that make many therapies possible are a blessing for patients. Thanks to modern anesthetics, not only can surgical operations be conducted without causing pain, they are also used for various diagnostic procedures. Anesthetics can be very useful in therapies for stroke patients, as psychologists and physicians of the Friedrich Schiller University Jena (Germany) and the University Hospital Jena are now able to prove.

6 Nov 2012

Growing concern in Asia over resistance to artemisinin-based antimalarial medicines

"Growing resistance to a key anti-malarial drug derived from a shrub used in traditional Chinese medicine is threatening to roll back gains made in combating the disease," according to experts attending a U.N.-sponsored malaria conference that concluded on Friday in Sydney, Australia, the U.N. News Centre reports.

6 Nov 2012

Tengion receives U.S. patent allowance titled ‘Isolated Renal Cells and Uses Thereof’

Tengion, Inc., a leader in regenerative medicine, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/617,721, titled "Isolated Renal Cells and Uses Thereof."

5 Nov 2012

Study highlights potential treatment that reduces kidney growth

Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders, affecting one in every 1,000 people and responsible for up to ten percent of patients on dialysis worldwide. The disease is characterized by the development of cysts that lead to progressive kidney failure and necessitate dialysis or a kidney transplant in most patients aged around fifty. Moreover, the persistent cyst growth causes high blood pressure and painful complications.

5 Nov 2012

Pharmaceutical News

Elafin protein protects against inflammatory diseases

Scientists show how sorafenib can be dangerous to the heart

IRIN examines intellectual property protection in South Africa

Drug trio may reduce eliminate cardiac side effects of doxorubicin

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Cause of heart attacks or strokes may be different in some patients treated with anti-platelet drugs

LipoScience presents key findings related to LDL-P and CVD at AHA annual meeting

FDA grants Priority Review to ImmunoGen’s trastuzumab emtansine BLA

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

NAI receives U.S. patent allowance for sustained release beta-alanine products

Geldanamycin degrades VEGFR2 protein that triggers blood vessel growth

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

Seniors can play an important role in reducing risks associated with prescription medications

Sorin Group’s Mitroflow Valsalva Conduit now available in the U.S.

Low-dose aspirin effective at preventing serious blood clots

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Study shows how local anesthetics can improve motor skills of patients after stroke

Growing concern in Asia over resistance to artemisinin-based antimalarial medicines

Tengion receives U.S. patent allowance titled ‘Isolated Renal Cells and Uses Thereof’

Study highlights potential treatment that reduces kidney growth

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News